DaVita Inc
NYSE:DVA

Watchlist Manager
DaVita Inc Logo
DaVita Inc
NYSE:DVA
Watchlist
Price: 165.63 USD -1.39% Market Closed
Market Cap: 13.6B USD
Have any thoughts about
DaVita Inc?
Write Note

DaVita Inc
Total Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

DaVita Inc
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
DaVita Inc
NYSE:DVA
Total Equity
$386.7m
CAGR 3-Years
-30%
CAGR 5-Years
-30%
CAGR 10-Years
-23%
Chemed Corp
NYSE:CHE
Total Equity
$1.2B
CAGR 3-Years
17%
CAGR 5-Years
13%
CAGR 10-Years
11%
Quest Diagnostics Inc
NYSE:DGX
Total Equity
$6.8B
CAGR 3-Years
2%
CAGR 5-Years
4%
CAGR 10-Years
5%
CVS Health Corp
NYSE:CVS
Total Equity
$74.9B
CAGR 3-Years
0%
CAGR 5-Years
4%
CAGR 10-Years
7%
Cigna Corp
NYSE:CI
Total Equity
$42.1B
CAGR 3-Years
-4%
CAGR 5-Years
-1%
CAGR 10-Years
14%
Laboratory Corporation of America Holdings
NYSE:LH
Total Equity
$8.2B
CAGR 3-Years
-8%
CAGR 5-Years
2%
CAGR 10-Years
11%
No Stocks Found

DaVita Inc
Glance View

Market Cap
13.7B USD
Industry
Health Care

DaVita Inc. has emerged as a leading healthcare provider specializing in kidney care, operating over 2,800 outpatient dialysis centers across the United States and 10 additional countries. Founded in 1994, the company has made significant strides in enhancing the quality of life for individuals battling chronic kidney disease. With a mission deeply rooted in patient care, DaVita focuses on delivering comprehensive treatment and support, ensuring that patients receive not only dialysis services but also vital education and resources for managing their condition. This commitment to patient-centric care has positioned DaVita as a notable player in the burgeoning healthcare sector, making it an attractive investment opportunity for those interested in the resilience and growth potential within the industry. From an investor's perspective, DaVita represents a blend of stability and growth potential, driven by an aging population that increasingly requires kidney care services. The company benefits from a favorable reimbursement landscape and has implemented operational efficiencies that enhance profitability. In recent years, DaVita has also ventured into value-based care initiatives, which align incentives towards improved patient outcomes rather than volume. This strategic pivot not only secures a sustainable revenue model but also highlights the company’s adaptability in a rapidly changing healthcare environment. As such, DaVita stands out in the investment community, offering a chance to capitalize on a vital sector poised for expansion, all while contributing to the well-being of countless patients.

DVA Intrinsic Value
228.68 USD
Undervaluation 28%
Intrinsic Value
Price

See Also

What is DaVita Inc's Total Equity?
Total Equity
386.7m USD

Based on the financial report for Sep 30, 2024, DaVita Inc's Total Equity amounts to 386.7m USD.

What is DaVita Inc's Total Equity growth rate?
Total Equity CAGR 10Y
-23%

Over the last year, the Total Equity growth was -68%. The average annual Total Equity growth rates for DaVita Inc have been -30% over the past three years , -30% over the past five years , and -23% over the past ten years .

Back to Top